The Bio Report spoke to Bill Hagstrom, CEO of Octave, about the company’s efforts to harness novel measurements of disease to individualize care, the case it’s making with payers, and why the company is starting with MS.

The Bio Report spoke to Matthew Price, co-founder, executive vice president, and chief operating officer of Phosplatin, about the company’s lead therapy, its multiple mechanisms of action, and why it may have benefit in a broad range of cancers.

The Bio Report spoke to Farlan Veraitch, co-founder and chief scientific officer of Ori, about the challenges of manufacturing cell and gene therapies, how the company’s platform addresses those issues, and why it is initially focusing on CAR-T cell therapies.

The Bio Report spoke to Shlomi Raz, CEO of Eleusis, about of the case for psychedelics as treatments for inflammatory conditions, how they work, and what challenges the development of these drugs pose.

The Bio Report this week speaks to Jeff Bluestone, CEO of Sonoma, about regulatory T cell therapies